clobazam has been researched along with Developmental Disabilities in 3 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clobazam was well tolerated and reduced drop seizure rates; high-dose CLB was more effective than low-dose CLB." | 2.74 | Clobazam in the treatment of Lennox-Gastaut syndrome. ( Abdulnabi, R; Collins, SD; Conry, JA; Kernitsky, L; Kormany, WN; Mitchell, WG; Ng, YT; Paolicchi, JM; Riley, B; Ritter, FJ; Stolle, J; Tracy, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imataka, G | 1 |
| Noguchi, M | 1 |
| Tsukada, K | 1 |
| Takahashi, T | 1 |
| Yamanouchi, H | 1 |
| Arisaka, O | 1 |
| Conry, JA | 1 |
| Ng, YT | 1 |
| Paolicchi, JM | 1 |
| Kernitsky, L | 1 |
| Mitchell, WG | 1 |
| Ritter, FJ | 1 |
| Collins, SD | 1 |
| Tracy, K | 1 |
| Kormany, WN | 1 |
| Abdulnabi, R | 1 |
| Riley, B | 1 |
| Stolle, J | 1 |
| Jung, M | 1 |
| Gabriel, KH | 1 |
| Stolle, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome[NCT00162981] | Phase 2 | 68 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and the 4-week maintenance period
| Intervention | Percent Reduction (Median) |
|---|---|
| Clobazam Low Dose | 29 |
| Clobazam High Dose | 93 |
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and 4-week maintenance period
| Intervention | Percent Reduction (Mean) |
|---|---|
| Clobazam Low Dose | 10.1 |
| Clobazam High Dose | 85.2 |
"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse." (NCT00162981)
Timeframe: Week 3
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very Much Improved | Much Improved | Minimally Improved | No Change | Minimally Worse | Much Worse | Very Much Worse | |
| Clobazam High Dose | 15 | 15 | 1 | 0 | 1 | 0 | 0 |
| Clobazam Low Dose | 7 | 9 | 9 | 3 | 0 | 1 | 0 |
"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse." (NCT00162981)
Timeframe: Week 7
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very Much Improved | Much Improved | Minimally Improved | No Change | Minimally Worse | Much Worse | Very Much Worse | |
| Clobazam High Dose | 16 | 11 | 1 | 0 | 1 | 0 | 0 |
| Clobazam Low Dose | 6 | 6 | 10 | 5 | 1 | 0 | 0 |
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and 4-week maintenance period
| Intervention | Percent of participants (Number) | |||
|---|---|---|---|---|
| ≥ 25% reduction | ≥ 50% reduction | ≥ 75% reduction | 100% reduction | |
| Clobazam High Dose | 32 | 30 | 23 | 8 |
| Clobazam Low Dose | 18 | 12 | 7 | 2 |
2 trials available for clobazam and Developmental Disabilities
| Article | Year |
|---|---|
Clobazam in the treatment of Lennox-Gastaut syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Developmenta | 2009 |
[ESES-syndrome in child- and adolescent psychiatry].
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Developmen | 2000 |
1 other study available for clobazam and Developmental Disabilities
| Article | Year |
|---|---|
Partial epilepsy and developmental delay in infant with ring chromosome 14.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Chromosome Disorders; Chromosomes, Human, Pair 1 | 2013 |